Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications

Condition(s) studied

Investigational drug(s) / intervention(s)

a blood test and urine sample collection.: The study is offered to all patients who meet the inclusion criteria during their pre-transplant assessment by the principal investigator (during an existing visit). Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged.

Study summary

Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.

Eligibility

Primary outcome measure(s)

• hepatic transplantation reduces arterial calcification — On the 7th day after surgery
  compare the percent of patients with AC progression before and after liver tranplantation

Trial sites (1)

More Centre Hospitalier Universitaire de Nice trials in France

Other trials for the same condition